← Back to Search

Time-Restricted Eating for Coronary Heart Disease (TREat-CR Trial)

N/A
Recruiting
Led By Paul Oh, MD
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Body mass index <18.5 kg/m^2 or clinical signs of cachexia
Type 2 diabetes that requires exogenous insulin
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-year
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the feasibility and safety of using a time-restricted eating diet during cardiac rehabilitation, and if it has any benefits compared to cardiac rehabilitation alone.

Who is the study for?
This trial is for men and women eligible for outpatient cardiac rehabilitation due to coronary artery disease, who are willing to follow the study's procedures. It excludes those with communication barriers, night shift workers, recent mothers or pregnant women, individuals with eating disorders or very low body weight, people who eat less than 3 meals a day or have an eating window under 12 hours, and diabetics on insulin.
What is being tested?
The study is testing if adding time-restricted eating (TRE), where participants eat all their meals within an 8-hour period each day, can improve the benefits of standard cardiac rehabilitation in patients with heart conditions. The effectiveness and safety of TRE as part of cardiac rehab will be evaluated.
What are the potential side effects?
While not explicitly stated in this summary, potential side effects from time-restricted eating may include hunger pangs outside of the eating window, fatigue during adjustment periods to new meal times, potential headaches or irritability associated with changes in blood sugar levels.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am underweight or show signs of severe weight loss.
Select...
I have type 2 diabetes and need insulin injections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adherence to the daily ≥16-hour fast for the 16-weeks of the cardiac rehabilitation program.
Cardiorespiratory fitness as measured by peak volume of oxygen consumption (VO2peak)
Fat mass
Secondary study objectives
Adverse events
Blood pressure
Fasted blood glucose
+8 more
Other study objectives
Caloric intake
Cardiac rehabilitation adherence
Macronutrient ratios
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard cardiac rehabilitation + TREExperimental Treatment2 Interventions
Participants in this group will receive the same standard assessment and individualized recommendations as the comparator group, but will also be counselled to restrict their eating to between 11 am and 7 pm during the program starting the evening of the consultation. They will also be advised to perform their home-based exercise sessions during the fasting period in the morning.
Group II: Standard cardiac rehabilitationActive Control1 Intervention
The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Time-Restricted Eating
2019
N/A
~160

Find a Location

Who is running the clinical trial?

University Health Network, TorontoOTHER
1,531 Previous Clinical Trials
504,262 Total Patients Enrolled
12 Trials studying Coronary Artery Disease
8,023 Patients Enrolled for Coronary Artery Disease
University of TorontoLead Sponsor
725 Previous Clinical Trials
1,115,632 Total Patients Enrolled
14 Trials studying Coronary Artery Disease
4,744 Patients Enrolled for Coronary Artery Disease
Paul Oh, MDPrincipal InvestigatorUniversity Health Network, Toronto
5 Previous Clinical Trials
379 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
169 Patients Enrolled for Coronary Artery Disease
Amy Kirkham, PhDPrincipal InvestigatorUniversity of Toronto, KITE Research Institute
1 Previous Clinical Trials
100 Total Patients Enrolled

Media Library

Standard cardiac rehabilitation Clinical Trial Eligibility Overview. Trial Name: NCT05075317 — N/A
Coronary Artery Disease Research Study Groups: Standard cardiac rehabilitation, Standard cardiac rehabilitation + TRE
Coronary Artery Disease Clinical Trial 2023: Standard cardiac rehabilitation Highlights & Side Effects. Trial Name: NCT05075317 — N/A
Standard cardiac rehabilitation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05075317 — N/A
~18 spots leftby Dec 2025